Oncternal Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Oncternal Therapeutics

29/10/2021 21:19

* Oncternal Therapeutics Inc  ONCT.OQ   ONCT.O  is expected
to show a rise in quarterly revenue when it reports results on
November 2 (estimated). 
* The San Diego, California-based company is expected to report 
a 121.9% increase in revenue to $1.298 million from $585
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Oncternal Therapeutics
Inc is for a loss of 16 cents per share. For the same quarter
last year, the company reported a loss of 22 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $16​, about 76.8% above​ its last closing
price of $3.72. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.14       -0.14      -0.16     Missed  -16.4
 Mar. 31 2021  -0.10       -0.10      -0.12     Missed  -20
 Dec. 31 2020  -0.19       -0.18      -0.09     Beat    50​
 Sep. 30 2020  -0.30       -0.30      -0.22     Beat    26.7
 ​​            ​                                        ​
                                                        ​
 This summary was machine generated October 29 at 20:19 GMT.  All
figures in US dollars unless otherwise stated